Although TargetScan identifies SMAD4 as a miR-146a target [58], our study found no differences in SMAD4 protein levels in PAH- and CTRL-hPASMCs upon miR-146a overexpression (Figure S4). Here, SMAD4 is linked to pulmonary arterial hypertension.